Assessment on the influence of TLR4 and DNA repair genes in laryngeal cancer susceptibility: a selective examination in a Romanian case control study

1. Sarafoleanu D. Tumorile maligne ale laringelui. In: Sarafoleanu C, editor. Esenţialul in laringologie. Editura Academiei Romane. Bucuresti. 2007. p. 322–351.Search in Google Scholar

2. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008 Jul 24;454(7203):436–44. DOI: 10.1038/nature0720510.1038/nature0720518650914Search in Google Scholar

3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–74. DOI: 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.01321376230Search in Google Scholar

4. Peltanova B, Raudenska M, Masarik M. Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review. Molecular Cancer. 2019 Mar 30;18(1):63. DOI: 10.1186/s12943-019-0983-510.1186/s12943-019-0983-5644117330927923Search in Google Scholar

5. Barnes L, Tse LLY, Hunt Jl, Brandwein-Gensler M, Urken M, Slootwef P, et al. Tumours of the hypopharynx, larynx and trachea: Introduction. In: Barnes L, Evenson JW, Reichart P, Sidransky D, editors. World Health Classification of Tumors Pathology and Genetics of Head and Neck Tumors. IARC Press. Lyon. 2005. p.109–120.Search in Google Scholar

6. Armstrong WB, Vokes DE, Verma SP. Malignant tumors of the larynx. In: Flint PW, Haughey BH, Lund V, Niparko JK, Robbins KT, Thomas JR, Lesperance MM, editors. Cummings Otolaryngology Head and Neck surgery. Sixth Edition. Elsevier. Philadelphia. 2014. p.1880–1923.Search in Google Scholar

7. Akira S, Uematsu S, Takeuchi O. Pathogen Recognition and Innate Immunity. Cell. 2006 Feb 24;124(4):783–801. DOI: 10.1016/j.cell.2006.02.01510.1016/j.cell.2006.02.01516497588Search in Google Scholar

8. Ferwerda B, McCall MB, Verheijen K, Kullberg B-J, van der Ven AJ, Van der Meer JW, et al. Functional Consequences of Toll-like Receptor 4 Polymorphisms. Mol Med. 2008;14(5–6):346–52. DOI: 10.2119/2007-00135.Ferwerda10.2119/2007-00135.Ferwerda221576518231573Search in Google Scholar

9. Oblak A, Jerala R. Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol. 2011;2011:609579. DOI: 10.1155/2011/60957910.1155/2011/609579321629222110526Search in Google Scholar

10. Sato Y, Goto Y, Narita N, Hoon DSB. Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenviron. 2009 Aug 15;2(Suppl 1):205–14. DOI: 10.1007/s12307-009-0022-y10.1007/s12307-009-0022-y275633919685283Search in Google Scholar

11. Mai CW, Kang YB, Pichika MR. Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. Onco Targets Ther. 2013 Nov 5;6:1573–87. DOI: 10.2147/OTT.S5083810.2147/OTT.S50838382179224235843Search in Google Scholar

12. Zhu L, Yuan H, Jiang T, Wang R, Ma H, Zhang S. Association of TLR2 and TLR4 Polymorphisms with Risk of Cancer: A Meta-Analysis. PLOS ONE. 2013 Dec 20;8(12):e82858. DOI: 10.1371/journal.pone.008285810.1371/journal.pone.0082858386972324376595Search in Google Scholar

13. Sancar A. Mechanisms of DNA excision repair. Science. 1994 Dec 23;266(5193):1954–6. DOI: 10.1126/science.780112010.1126/science.78011207801120Search in Google Scholar

14. Torgovnick A, Schumacher B. DNA repair mechanisms in cancer development and therapy. Front Genet. 2015; 6: 157 DOI: 10.3389/fgene.2015.0015710.3389/fgene.2015.00157Search in Google Scholar

15. Berwick M, Vineis P. Markers of DNA Repair and Susceptibility to Cancer in Humans: an Epidemiologic Review. J Natl Cancer Inst. 2000 Jun 7;92(11):874–97. DOI: 10.1093/jnci/92.11.87410.1093/jnci/92.11.874Search in Google Scholar

16. Caldecott KW, Aoufouchi S, Johnson P, Shall S. XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular “nick-sensor” in vitro. Nucleic Acids Res. 1996 Nov 15;24(22):4387–94. DOI: 10.1093/nar/24.22.438710.1093/nar/24.22.4387Search in Google Scholar

17. Khlifi R, Rebai A, Hamza-Chaffai A. Polymorphisms in human DNA repair genes and head and neck squamous cell carcinoma. J Genet. 2012 Dec 1;91(3):375–84. DOI: 10.1007/s12041-012-0193-z10.1007/s12041-012-0193-zSearch in Google Scholar

18. Wang M, Chu H, Zhang Z, Wei Q. Molecular epidemiology of DNA repair gene polymorphisms and head and neck cancer. J Biomed Res. 2013 May;27(3):179–92.Search in Google Scholar

19. Feng YZ, Liu YL, He XF, Wei W, Shen XL, Xie DL. Association between the XRCC1 Arg194Trp polymorphism and risk of cancer: evidence from 201 case-control studies. Tumor Biol. 2014 Nov 1;35(11):10677–97. DOI: 10.1007/s13277-014-2326-x10.1007/s13277-014-2326-xSearch in Google Scholar

20. Yi L, Xiao-feng H, Yun-tao L, Hao L, Ye S, Song-tao Q. Association between the XRCC1 Arg399Gln Polymorphism and Risk of Cancer: Evidence from 297 Case-Control Studies. PLOS ONE. 2013;8(10):e78071. DOI: 10.1371/journal.pone.007807110.1371/journal.pone.0078071Search in Google Scholar

21. Schultz P, Fribourg S, Poterszman A, Mallouh V, Moras D, Egly JM. Molecular Structure of Human TFIIH. Cell. 2000 Sep 1;102(5):599–607. DOI: 10.1016/S0092-8674(00)00082-910.1016/S0092-8674(00)00082-9Search in Google Scholar

22. Chen J, Suter B. Xpd, a Structural Bridge and a Functional Link. Cell Cycle. 2003 Nov 28;2(6):503–6. DOI: 10.4161/cc.2.6.55810.4161/cc.2.6.55814504460Search in Google Scholar

23. Fan L, Fuss JO, Cheng QJ, Arvai AS, Hammel M, Roberts VA, et al. XPD Helicase Structures and Activities: Insights into the Cancer and Aging Phenotypes from XPD Mutations. Cell. 2008 May 30;133(5):789–800. DOI: 10.1016/j.cell.2008.04.03010.1016/j.cell.2008.04.030305524718510924Search in Google Scholar

24. Coin F, Marinoni J-C, Rodolfo C, Fribourg S, Pedrini AM, Egly J-M. Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nat Genet. 1998 Oct;20(2):184–8. DOI: 10.1038/249110.1038/24919771713Search in Google Scholar

25. Mitra AK, Singh N, Garg VK, Chaturvedi R, Sharma M, Rath SK. Statistically significant association of the single nucleotide polymorphism (SNP) rs13181 (ERCC2) with predisposition to Squamous Cell Carcinomas of the Head and Neck (SCCHN) and Breast cancer in the north Indian population. J Exp Clin Cancer Res. 2009 Jul 18;28(1):104. DOI: 10.1186/1756-9966-28-10410.1186/1756-9966-28-104272438919615095Search in Google Scholar

26. Fu W, Xiao F, Zhang R, Li J, Zhao D, Lin X, et al. Association Between the Asp312Asn, Lys751Gln, and Arg156Arg Polymorphisms in XPD and the Risk of Prostate Cancer. Technol Cancer Res Treat. 2017 Dec;16(6):692–704. DOI: 10.1177/153303461772467810.1177/1533034617724678576207228797198Search in Google Scholar

27. Yin J, Vogel U, Ma Y, Guo L, Wang H, Qi R. Polymorphism of the DNA repair gene ERCC2 Lys751Gln and risk of lung cancer in a northeastern Chinese population. Cancer Genetics and Cytogenetics. 2006 Aug 1;169(1):27–32. DOI: 10.1016/j.cancergencyto.2006.03.00810.1016/j.cancergencyto.2006.03.00816875933Search in Google Scholar

28. Procopciuc LM, Osian G. Interaction between lifestyle factors and the XRCC1, XPD, and XRCC3 genetic variations modulates the risk for sporadic colorectal cancer. Revista Romana de Medicina de Laborator. 2014 Mar 1;22(1):129–41. DOI: 10.2478/rrlm-2014-000210.2478/rrlm-2014-0002Search in Google Scholar

29. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013 Nov 27;310(20):2191–4. DOI: 10.1001/jama.2013.28105310.1001/jama.2013.28105324141714Search in Google Scholar

30. de Miguel-Luken MJ, Chaves-Conde M, Carnero A. A genetic view of laryngeal cancer heterogeneity. Cell Cycle. 2016 Mar 3;15(9):1202–12. DOI: 10.1080/15384101.2016.115627510.1080/15384101.2016.1156275489450526940775Search in Google Scholar

31. Szczepański M, Stelmachowska M, Stryczyński L, Golusiński W, Samara H, Mozer-Lisewska I, et al. Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma. Eur Arch Otorhinolaryngol. 2007 May;264(5):525–30. DOI: 10.1007/s00405-006-0215-710.1007/s00405-006-0215-717165086Search in Google Scholar

32. Sikora J, Frydrychowicz M, Kaczmarek M, Brzezicha B, Mozer-Lisewska I, Szczepański M, et al. TLR receptors in laryngeal carcinoma - immunophenotypic, molecular and functional studies. Folia Histochemica et Cytobiologica. 2010 Dec 1;48(4):624–31. DOI: 10.2478/v10042-010-0077-010.2478/v10042-010-0077-021478107Search in Google Scholar

33. Bergmann C, Bachmann HS, Bankfalvi A, Lotfi R, Pütter C, Wild CA, et al. Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas. J Transl Med. 2011 Aug 21;9:139. DOI: 10.1186/1479-5876-9-13910.1186/1479-5876-9-139317060321854645Search in Google Scholar

34. Ding L, Jiang Q, Li G, Shen J, Du J, Lu X, et al. Comprehensive assessment of association between TLR4 gene polymorphisms and cancer risk: a systematic meta-analysis. Oncotarget. 2017 Nov 21;8(59):100593–602. DOI: 10.18632/oncotarget.2154310.18632/oncotarget.21543572504629246004Search in Google Scholar

35. Alimu N, Qukuerhan A, Wang S, Abdurehim Y, Kuyaxi P, Zhang B, et al. The association between XRCC1 polymorphism and laryngeal cancer susceptibility in different ethnic groups in Xinjiang, China. Int J Clin Exp Pathol. 2018 Sep 1;11(9):4595–604.Search in Google Scholar

36. Li F, Wang J, Chen M. Single nucleotide polymorphisms in DNA repair genes and the risk of laryngeal cancer: A meta-analysis. Biomedicine & Pharmacotherapy. 2016 Mar 1;78:92–100. DOI: 10.1016/j.biopha.2015.12.01910.1016/j.biopha.2015.12.019Search in Google Scholar

37. Olshan AF, Watson MA, Weissler MC, Bell DA. XRCC1 polymorphisms and head and neck cancer. Cancer Lett. 2002;178:181–6 DOI: 10.1016/S0304-3835(01)00822-910.1016/S0304-3835(01)00822-9Search in Google Scholar

38. Huang W-Y, Olshan AF, Schwartz SM, Berndt SI, Chen C, Llaca V, et al. Selected Genetic Polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and Risk of Head and Neck Cancer: A Pooled Analysis. Cancer Epidemiol Biomarkers Prev. 2005 Jul 1;14(7):1747–53. DOI: 10.1158/1055-9965.EPI-05-016210.1158/1055-9965.EPI-05-016216030112Search in Google Scholar

39. Hu Z, Ma H, Chen F, Wei Q, Shen H. XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1810–1818 DOI: 10.1158/1055-9965.EPI-04-079310.1158/1055-9965.EPI-04-079316030121Search in Google Scholar

40. Varzim G, Monteiro E, Silva RA, Fernandes J, Lopes C. CYP1A1 and XRCC1 gene polymorphisms in SCC of the larynx. Eur J of Cancer Prev. 2003 Dec;12(6):495–9. DOI: 10.1097/00008469-200312000-0000810.1097/00008469-200312000-0000814639127Search in Google Scholar

41. Chen W, Wang ZY, Xu FL, Wu KM, Zhang Y, Xu L, et al. Association of XRCC1 genetic polymorphism (Arg399Gln) with laryngeal cancer: a meta-analysis based on 4,031 subjects. Tumor Biol. 2014 Feb 1;35(2):1637–40. DOI: 10.1007/s13277-013-1225-x10.1007/s13277-013-1225-x24194393Search in Google Scholar

42. Wu WQ, Zhang LS, Liao SP, Lin XL, Zeng J, Du D. Association between XRCC1 polymorphisms and laryngeal cancer susceptibility in a Chinese sample population. Genet Mol Res. 2016 Oct 5;15(4). DOI: 10.4238/gmr.1504852510.4238/gmr.1504852527808358Search in Google Scholar

43. Yuan H, Li H, Ma H, Niu Y, Wu Y, Zhang S, et al. Genetic polymorphisms in key DNA repair genes and risk of head and neck cancer in a Chinese population. Exp Ther Med. 2012 Apr;3(4):719–24. DOI: 10.3892/etm.2012.47610.3892/etm.2012.476343858622969958Search in Google Scholar

44. Wu W, Liu L, Yin Z, Guan P, Li X, Zhou B. Association of X-Ray Repair Cross-Complementing Group 1 Arg194Trp, Arg399Gln and Arg280His Polymorphisms with Head and Neck Cancer Susceptibility: A Meta-Analysis. PLOS ONE. 2014;9(1):e86798. DOI: 10.1371/journal.pone.008679810.1371/journal.pone.0086798390744624497981Search in Google Scholar

45. Lou Y, Peng W, Cao D, Xie J, Li H, Jiang Z. DNA Repair Gene XRCC1 Polymorphisms and Head and Neck Cancer Risk: An Updated Meta-Analysis Including 16344 Subjects. PLOS ONE. 2013 Sep 23;8(9):e74059. DOI: 10.1371/journal.pone.007405910.1371/journal.pone.0074059378116824086310Search in Google Scholar

46. Lin H, Lin D, Zheng C. Association of XPD Lys751Gln polymorphism with head and neck cancer susceptibility: evidence from 11,443 subjects. Diagn Pathol. 2014 Jan 20;9:15. DOI: 10.1186/1746-1596-9-1510.1186/1746-1596-9-15391608124443924Search in Google Scholar

47. Yuan H, Niu YM, Wang RX, Li HZ, Chen N. Association between XPD Lys751Gln polymorphism and risk of head and neck cancer: a meta-analysis. Genet Mol Res. 2011;10(4):3356–64 DOI: 10.4238/2011.November.22.610.4238/2011.November.22.622179996Search in Google Scholar

48. Hou S-M, Ryk C, Kannio A, Angelini S, Fält S, Nyberg F, et al. Influence of common XPD and XRCC1 variant alleles on p53 mutations in lung tumors. Environmental and molecular mutagenesis. 2003 Feb 1;41:37–42. DOI: 10.1002/em.1012810.1002/em.1012812552590Search in Google Scholar

49. Zhong S, Nukui T, Buch S, Diergaarde B, Weissfeld LA, Grandis J, et al. Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependent. Cancer Epidemiol Biomarkers Prev. 2011 Nov;20(11):2429–37. DOI: 10.1158/1055-9965.EPI-11-052010.1158/1055-9965.EPI-11-0520321090721890746Search in Google Scholar

50. An J, Liu Z, Hu Z, Li G, Wang L-E, Sturgis EM, et al. Potentially functional single nucleotide polymorphisms in the core nucleotide excision repair genes and risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 2007 Aug 1;16(8):1633–8 DOI: 10.1158/1055-9965.EPI-07-025210.1158/1055-9965.EPI-07-025217684138Search in Google Scholar

51. Sun Y, Tan L, Li H, Qin X, Liu J. Association of NER pathway gene polymorphisms with susceptibility to laryngeal cancer in a Chinese population. Int J Clin Exp Pathol. 2015 Sep 1;8(9):11615–21.Search in Google Scholar